Core Viewpoint - Nanwei Technology (688690) expects to achieve a net profit attributable to shareholders of the parent company between 128 million yuan and 145 million yuan for the fiscal year 2025, representing a year-on-year growth of 54.51% to 75.03% [1] Group 1: Financial Performance - The company's core business in chromatographic fillers and chromatography media products saw a sales revenue increase of approximately 23% [1] - Sales revenue for liquid chromatography columns and sample pre-treatment products experienced an increase of about 32% [1]

纳微科技公告，预计2025年年度实现归属于母公司所有者的净利润1.28亿元至1.45亿元，较上年度（法 定披露数据）相比，将增加0.45亿元至0.62亿元，同比增长54.51%至75.03%。预计2025年年度实现营业 收入9.18亿元至9.3亿元，较上年度（法定披露数据）相比，将增加1.36亿元至1.48亿元，同比增长 17.32%至18.86%。预计2025年年度实现扣除非经常性损益后归属母公司所有者的净利润1.12亿元至1.28 亿元，较上年度（法定披露数据）相比，将增加0.46亿元至0.62亿元，同比增长70.02%至94.31%。 ...

Core Viewpoint - Biomanufacturing is identified as a key future industry in China's 14th Five-Year Plan, expected to create a market worth trillions in the next decade, driven by advancements in technology and policy support [2][5]. Group 1: Industry Overview - The biomanufacturing industry in China is nearing a total scale of 1 trillion yuan, with fermentation capacity accounting for over 70% of the global total [2][4]. - Shenzhen has become a hub for biomanufacturing, with 40% of newly established companies in this sector located there in the past three years, showcasing a significant industry clustering effect [4]. - The industry is supported by a comprehensive system of policy, funding, and technological advancements as outlined in the 14th Five-Year Plan [5]. Group 2: Key Enterprises - The article identifies 100 core enterprises in biomanufacturing, spanning the entire industry chain from upstream technology development to downstream commercial applications [7]. - Notable companies include: - Huada Technology, a leader in gene sequencing technology [17]. - Kaisa Biotech, which has achieved over 80% market share in the global long-chain dicarboxylic acid market [21]. - WuXi Biologics, representing China's capabilities in the global biopharmaceutical industry [27]. Group 3: Upstream Innovations - The upstream sector focuses on providing essential tools and technologies for research and production, with a shift towards domestic innovation and smart integration [16]. - Key trends include the localization of critical tools and the rise of AI-driven platform companies that enhance research efficiency [16][17]. - Over 75% of the 20 identified upstream enterprises are private, indicating a vibrant innovation landscape [16]. Group 4: Midstream Developments - The midstream sector is characterized by a dual structure of "upgraders" and "disruptors," with companies like Meihua Biotech and Chuaning Biotech leading in traditional fermentation while others like Kaisa Biotech innovate with new bioproducts [20][21]. - This segment contains the highest number of enterprises, with 40 out of the 100 identified companies, emphasizing the importance of production capacity and cost control [20]. Group 5: Downstream Applications - The downstream sector serves as a critical market for biomanufacturing, focusing on medical, consumer, and agricultural applications [25]. - Companies like Muyuan Foods exemplify the cost-saving potential of biomanufacturing in agriculture, while WuXi Biologics and Kelaiying represent the pharmaceutical sector's output capabilities [26][27]. - Future trends indicate a broadening of applications into new areas such as biobased textiles and environmental remediation [27].

Core Insights - The Chinese nanosphere industry is experiencing rapid growth, with a projected market size of approximately 4.236 billion yuan in 2024, representing a year-on-year increase of 5.40% [1][7]. Industry Overview - Nanospheres are micron-sized spheres with nanoscale pore structures, characterized by high specific surface area and unique physical and chemical properties. They are widely used in drug delivery, liquid crystal displays, bi separation, medical diagnostics, and optoelectronic materials [2][4]. - The primary materials for nanospheres are classified into natural biomaterials (such as chitosan and collagen) and synthetic polymers (like PLGA and PVA) [2]. Nanosphere Classification - Nanospheres can be categorized based on preparation methods, including ion crosslinking, emulsion-solvent evaporation, and microfluidic technology, each with distinct principles, applicable materials, and performance characteristics [4]. Industry Chain - The upstream of the nanosphere industry includes raw materials such as chitosan, starch, cellulose, and various polymers. The midstream involves the production and manufacturing of nanospheres, while the downstream applications span drug delivery, bi separation, in vitro diagnostics, LCD spacers, conductive materials, and light diffusion films [5][6]. Market Size - The Chinese nanosphere industry is on a growth trajectory, with a market size expected to reach approximately 4.236 billion yuan in 2024, marking a 5.40% increase from the previous year [1][7]. Key Companies - Suzhou Nanwei Technology Co., Ltd. is recognized as the industry leader, leveraging proprietary technologies for precise control over sphere size and surface properties. In the first three quarters of 2025, the company reported revenues of 671 million yuan, a 22.01% increase year-on-year [8][9]. - Xian Lanyao Technology Co., Ltd. is a leading player in the adsorption separation materials sector, focusing on life sciences. The company reported revenues of 193 million yuan in the first three quarters of 2025, reflecting a 2.20% year-on-year growth [10]. Industry Development Trends 1. **Technological Innovation**: The preparation technology for nanospheres is advancing towards ultra-high precision, functional integration, and green transformation, with a focus on AI-assisted design and biodegradable materials [11]. 2. **Diverse Application Demand**: The biopharmaceutical sector remains the core growth area for nanospheres, with increasing demand in electronic displays and environmental applications, leading to a surge in market demand [12]. 3. **Domestic Substitution**: The market is transitioning from foreign monopoly to rapid growth of local enterprises, with domestic leaders like Nanwei Technology gaining market share due to competitive pricing and technological advantages [12].

证券日报网讯1月9日，纳微科技在互动平台回答投资者提问时表示，公司目前专注于生物制药分离纯化 及色谱分析检测主营业务，没有布局拉曼检测技术领域。 ...

Summary of Conference Call Records Industry Overview - The life sciences service sector, particularly the CXO segment, continues to experience high growth and is expected to deliver strong performance in 2026, benefiting from the upward cycle in innovative drugs and improved investment conditions [1][2][3] Key Companies and Performance - Notable companies in the life sciences service industry include: - **Hao Yuan Medicine**: Q3 revenue growth close to 30%, with a non-recurring profit growth of 70%. The company has secured orders exceeding 630 million yuan, a 50% year-on-year increase [2][8] - **Bai Ao Sai Tu**: Achieved a revenue growth of 60% in Q3 and recorded its first annual profit, with significant potential in humanized mouse sales and antibody business [2][8] - **WuXi AppTec**: Expected to see over 60% revenue growth in the ADC sector in the first half of 2026, with a strong order backlog [10][19] - **Kailai Ying**: Positioned well in the ADC market, with significant growth potential [10][19] - **Yangguang Nuohe**: Anticipated to achieve a profit of 300 million yuan in 2026, with a promising drug pipeline [20] Financial Performance - In the first three quarters of 2025, 16 representative life sciences service companies reported revenue and profit growth rates of high single digits and double digits, respectively. In Q3 alone, revenue and profit growth rates were double digits and 50%, indicating significant operational improvement [4][6] - The gross profit margin is expected to improve due to a clearer competitive landscape, leading to enhanced industry profitability [4] Market Trends - The overseas market is benefiting from improved investment conditions and the Federal Reserve's interest rate cuts, leading to an increase in the share of overseas business and expanding global market potential [7] - The domestic CRO market is experiencing a price recovery trend after years of intense competition, with expectations for more significant price improvements by 2027 as supply conditions stabilize [11][12] Growth Opportunities - The ADC and small nucleic acid sectors are projected to bring substantial order increases in 2026, with companies like WuXi AppTec and Hao Yuan Medicine expected to lead this growth [10][19] - The CRO sector is seeing a shift towards innovation, with companies like Yangguang Nuohe and Chengdu Xian Dao making progress in developing innovative drugs [13] Investment Recommendations - Recommended companies for investment include: - **WuXi AppTec**: Strong growth in peptide business and expected to achieve significant revenue increases [14][17] - **Kailai Ying**: Leading in peptide capacity expansion [14] - **Tigermed**: Positioned well in the CRO market with growth potential [21] - **Norseg and Prasis**: Expected to benefit from overall industry trends [17] Conclusion - The life sciences service industry is poised for continued growth, driven by innovative drug development, improved investment conditions, and a recovering market landscape. Key players are expected to deliver strong financial performance, making them attractive investment opportunities.

Core Viewpoint - The article discusses the performance of the Zhongzheng 1000 ETF Enhanced (561280), highlighting its opening price and the performance of its major holdings since its inception on August 31, 2023, which has yielded a return of 57.53% [1]. Group 1: ETF Performance - The Zhongzheng 1000 ETF Enhanced (561280) opened at 1.578 yuan, experiencing a decline of 0.19% [1]. - Since its establishment on August 31, 2023, the fund has achieved a return of 57.53% [1]. - The fund's performance over the past month has been a return of 6.26% [1]. Group 2: Major Holdings - Major stocks in the fund include: - Boqian New Materials, which opened with an increase of 0.68% [1]. - Haoyuan Pharmaceutical, which rose by 0.78% [1]. - Yingjixin, which increased by 0.56% [1]. - Caixun Co., which saw a slight increase of 0.08% [1]. - Jinma Leisure, which rose by 0.41% [1]. - Panjiang Co., which remained unchanged [1]. - Jindawei, which decreased by 0.10% [1]. - Yiyuan Communication, which increased by 0.43% [1]. - Minxin Co., which remained unchanged [1]. - Nami Technology, which rose by 0.34% [1]. [1]

北京市中伦（上海）律师事务所 关于苏州纳微科技股份有限公司 2025 年第二次临时股东会 法律意见书 二〇二五年十二月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 法律意见书 北京市中伦（上海）律师事务所 关于苏州纳微科技股份有限公司 2025 年第二次临时股东会 法律意见书 致苏州纳微科技股份有限公司： 人员和召集人资格、会议表决程序及表决结果是否符合《公司法》等法律、法规、 规范性文件及《公司章程》、《股东会规则》的规定发表意见，不对会议审议的议 案内容以及该等议案所表述的事实或数据的真实性及 ...

证券代码：688690 证券简称：纳微科技 公告编号：2025-045 苏州纳微科技股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （四） 表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 1、本次股东会采用现场投票和网络投票相结合的方式进行表决； 2、本次会议由公司董事会召集，董事长江必旺博士主持； 3、本次会议的召集召开程序、表决方式和表决程序符合《中华人民共和国公司 法》及《苏州纳微科技股份有限公司章程》的有关规定，会议决议合法、有效。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 12 月 26 日 （二） 股东会召开的地点：江苏省苏州市工业园区百川街 2 号研发中心大楼会 议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 87 | | --- | --- | | 普通股股东人数 | 87 | | ...

Group 1 - The core viewpoint of the news is that Nami Technology has shown a significant increase in stock price and financial performance, indicating a positive market sentiment and growth potential [1][2]. - As of December 24, Nami Technology's stock price increased by 2.02% to 25.75 CNY per share, with a market capitalization of 10.398 billion CNY [1]. - The company has experienced a year-to-date stock price increase of 46.83%, with a recent slight decline over the past 20 days of 4.20% [1]. Group 2 - Nami Technology, established on October 22, 2007, specializes in the research, production, and sales of high-performance nano-microsphere materials, serving sectors such as biomedicine and diagnostics [2]. - The company's revenue composition includes 57.62% from chromatography fillers and media, 19.72% from chromatography instruments and accessories, and 10.44% from liquid chromatography columns and sample pretreatment products [2]. - For the period from January to September 2025, Nami Technology reported a revenue of 671 million CNY, reflecting a year-on-year growth of 22.01%, and a net profit of 108 million CNY, marking a significant increase of 156.56% [2]. Group 3 - Nami Technology has distributed a total of 115 million CNY in dividends since its A-share listing, with 86.8418 million CNY distributed over the past three years [3]. - As of September 30, 2025, the number of shareholders increased to 16,100, with an average of 25,091 circulating shares per person, a decrease of 6.16% from the previous period [2][3].